Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin B
- Conditions
- Infertility
- Interventions
- Other: Cytochalasin B use in ICSI handling medium
- Registration Number
- NCT03663634
- Lead Sponsor
- Ibn Sina Hospital
- Brief Summary
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Cytochalasin B serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Cytochalasin B during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 987
- All ICSI candidates patients
- No exclusion
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Handling Medium Supplemented with Cytochalasin B Cytochalasin B use in ICSI handling medium -
- Primary Outcome Measures
Name Time Method oocyte survival rate 6 days of culture number of survived oocyte after intracytoplasmic sperm injection
- Secondary Outcome Measures
Name Time Method fertilization rate 6 days of culture number of fertilized oocytes per metaphase II injected
clinical pregnancy rate three months number of women with a heartbeat at week 4 or more after embryo transfer
ongoing pregnancy rate four months number of women with continued pregnancy after twelve weeks of gestation
blastocyst formation rate 6 days of culture number of formed blastocyst per fertilized oocyte
embryo utilization rate 6 days of culture number of embryo transferred added to number of those cryopreserved per fertilized oocyte
Trial Locations
- Locations (1)
IbnSina IVF Center
🇪🇬Sohag, Egypt